

1 **Title:**

2 **Incorporating Nonlinear Kinetics to Improve the Predictive**
3 **Performance of Population Pharmacokinetic Models for Ciclosporin**
4 **in Adult Renal Transplant Recipients: A Comparison of Modelling**
5 **Strategies**

6

7 Jun-Jun Mao¹, Zheng Jiao^{1,3*}, Xiao-Yan Qiu¹, Ming Zhang², Ming-Kang Zhong¹

8 1 Department of Pharmacy, Huashan Hospital, Fudan University, 12 Middle Urumqi
9 Road, Shanghai, 200040, China

10 2 Department of Nephropathy, Huashan Hospital, Fudan University, 12 Middle Urumqi
11 Road, Shanghai, 200040, China

12 3 Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University,
13 241 West Huaihai Road, Shanghai, 200030, China

14

15 **Corresponding author:**

16 Zheng Jiao, PhD

17 Professor of Clinical Pharmacy,

18 ¹ Department of Pharmacy, Huashan Hospital, Fudan University

19 12 Middle Urumqi Road, Shanghai, 200040, China

20 ² Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University

21 241 West Huaihai Road, Shanghai, 200030, China

22 Tel: (8621) 5288 8712 Fax: (8621) 62486927

23 Email: zjiao@fudan.edu.cn

24

25 **Submitting author:**

26 Jun-Jun Mao

27 Email: jmao12@fudan.edu.cn

28

29 **Principal Investigator statement:**

30 NOTE: The authors confirm that the Principal Investigator for this paper is Zheng Jiao and
The authors confirm that the Principal Investigator for this paper is Zheng Jiao and practice.

31 that he had direct clinical responsibility for patients.

32

33 **Running head:**

34 Improving ciclosporin predictive modeling using nonlinear kinetics

35

36 **Word Counts:**

37 Abstract: 250; Main text (Introduction, Methods, Results and Discussion): 3978

38

39 **Number of tables and figures:** 3/2

40

41 **Number of supplemental texts, tables and figures:** 3/1/2

42

43 **Number of references:** 49

44

45 **Keywords:** ciclosporin, population pharmacokinetics, nonlinear kinetics, modelling
46 strategies

47 **Abstract**

48 **Aim**

49 Ciclosporin (CsA) has been shown to follow nonlinear pharmacokinetics in renal transplant recipients
50 who received Neoral-based triple immunosuppressive therapy. Some of these nonlinear properties have
51 not been fully considered in population pharmacokinetic (popPK) analysis. Therefore, the aim of this
52 study was to determine the potential influence of nonlinearity and the functional forms of covariates on
53 model predictability.

54 **Methods**

55 A total of 2969 CsA whole-blood measurements, including 1328 pre-dose and 1641 2-h post-dose
56 concentrations, were collected from 173 patients who underwent their first renal transplantation. Four
57 popPK models based on different modelling strategies were developed to investigate the discrepancy
58 between empirical and theory-based, linear and nonlinear compartmental kinetic models and empirical
59 formulae on model predictability. Prediction-based and simulation-based diagnostics (prediction-
60 corrected visual predictive checks) were performed to determine the stability and predictive performance
61 of these four models.

62 **Results**

63 Model predictability improved when nonlinearity was considered. The theory-based nonlinear model
64 which incorporated nonlinear property based on known theoretical relationships performed better than
65 the other two compartmental models. The nonlinear Michaelis-Menten model showed a remarkable
66 improvement in predictive performance over that of the other three compartmental models. The saturated
67 binding of CsA to erythrocytes, and auto-inhibition that arose from the inhibitory effects of CsA on
68 *CYP3A4/P-gp* and CsA-prednisolone drug interaction may have contributed to the nonlinearity.

69 **Conclusions**

70 Incorporating nonlinear properties are likely to be a promising approach for improving CsA model
71 predictability. However, CsA nonlinear kinetics resources need further investigation. Until then,
72 Michaelis-Menten empirical model can be used for CsA dose adjustments.

73

74 **What is already known about this subject:**

- 75 • CsA in renal transplant recipients receiving Neoral-based triple immunosuppressive therapy
76 followed nonlinear pharmacokinetics.
- 77 • Nonlinearity is rarely incorporated into CsA population pharmacokinetic (popPK) modelling
78 processes.

79 **What this study adds:**

- 80 • Four popPK models based on different modelling strategies were developed to investigate the
81 discrepancy between empirical and theory-based compartmental kinetic models and empirical
82 formulae, as well as the effect of nonlinearity on CsA model predictability.
- 83 • Based on the four models, incorporating nonlinear properties is likely to be a promising approach
84 for improving CsA model predictability.
- 85 • Saturated distribution into red blood cells, and auto-inhibition that arose from the inhibitory effects
86 of CsA on *CYP3A4*/P-gp and CsA-prednisolone drug interaction may be the main sources of CsA
87 PK nonlinearity.

88 **1 Introduction**

89 Ciclosporin (CsA), an immunosuppressant with a narrow therapeutic range and considerable pharmacokinetic (PK)
90 variability, is widely used to prevent allograft rejection after renal transplantation [1, 2]. CsA has low oral bioavailability
91 (approximately 25%, range 10% - 89%) [3] due to its erratic gastrointestinal absorption and the combined activity of
92 [cytochrome P450 \(CYP\) 3A](#) and [P-glycoprotein \(P-gp\)](#) [1]. It is extensively bound to erythrocytes [3], metabolised by
93 [CYP3A4](#) and [CYP3A5](#) [4], and then mainly eliminated in bile [5, 6].

94 The absorption and disposition of conventionally formulated CsA are considered dose-dependent [7]. To reduce oral
95 absorption variability and improve CsA dose linearity, a new oral microemulsion of CsA (Neoral[®], Novartis) was
96 formulated [8]. Mueller *et al.* [9] compared the PK of Neoral with that of the conventional CsA formulation and concluded
97 that Neoral had superior dose linearity with exposure after oral administration. However, it should be noted that this study
98 was conducted in healthy volunteers administered a single oral dose.

99 In contrast to single-dose PK studies, the in-vivo behaviour of drugs in clinical practice is co-influenced by multiple
100 intrinsic/extrinsic factors including demographic factors, genetic polymorphisms of drug metabolising enzymes and
101 transporters, disease progression, concomitant medications, and most importantly their combined effects [10]. As
102 determined by population pharmacokinetic (popPK) analyses, CsA is revealed to have a nonlinear PK in renal transplant
103 recipients [11, 12].

104 The observed nonlinearity phenomenon may be partially attributed to metabolic enzyme/transporter protein
105 interactions. In addition to CYP3A and P-gp substrates, CsA potently inhibits transporter proteins P-gp and OATP1B1,
106 as well as CYP3A4 [13-16]. Additionally, CsA is typically used in combination with anti-proliferative drugs and
107 corticosteroids in clinical settings [17]. When co-administered with steroids, it is able to activate pregnane X receptor
108 (PXR), and then up-regulates *CYP3A* and *MDR1* gene expression [18-20]. CsA-prednisolone drug interaction may cause
109 CsA PK nonlinearity. Furthermore, the saturated binding of CsA to erythrocytes may also contribute to nonlinearity [3].

110 Obtaining an accurate description of the complex PK processes of CsA is challenging but useful in supporting dosage
111 adaptation. Numerous studies have described the popPK characteristics of CsA in adult renal transplant recipients [11,
112 21]. The available models have identified covariates mainly through empirical investigation. No consistent covariates or
113 their functional forms in models were identified in those studies. Some of the nonlinear properties described above are
114 not fully considered in modelling processes. Including covariate effects based on theoretical mechanisms rather than
115 empirically identifying relationships should lead to more consistent results [22].

116 To determine the potential influence of nonlinearity and the functional forms of covariates on model predictability,
117 four popPK models based on different modelling strategies were developed. These models investigated the discrepancy
118 between empirical and theory-based compartmental kinetic models and empirical formulae, as well as the effect of
119 nonlinearity on model predictability. Their predictive performance was evaluated by prediction- and simulation-based
120 diagnostics, as previously reported [11, 23].

121 **2 Materials and Methods**

122 **2.1 Patients**

123 Data from 173 adults (112 male and 61 female), who underwent their first renal transplantation at Huashan Hospital
124 were retrospectively collected. Patients were randomly divided into two groups: 121 for model development and 52 for
125 model evaluation. Whole-blood samples of CsA pre-dose concentration (C_0) and 2-h post-dose concentration (C_2) were
126 monitored. Demographic and pathophysiological data were obtained during routine clinical visits from July 2003 to
127 December 2016. Patient follow-up was conducted up to three years after surgery. Those undergoing dialysis treatments
128 were excluded from this study. The observations from the first two postoperative days were excluded to ensure that the
129 measured CsA concentrations were relatively stable.

130 The study protocols were approved by the Ethics Committee of Huashan Hospital and written informed consent was
131 obtained from all subjects.

132 **2.2 Immunosuppressive Therapy**

133 All patients received combined immunosuppressive therapy comprising a CsA microemulsion (Neoral[®]; Novartis
134 Pharma Schweiz AG, Emmerbach, Germany), mycophenolate mofetil (MMF, CellCept[®]; Roche Pharma Ltd, Shanghai,
135 China) and corticosteroids. Initial CsA dosage was 5 mg kg⁻¹ day⁻¹, administered as two doses under fasting conditions
136 immediately after surgery. CsA concentration were regularly monitored to adjust the dosage and achieve target
137 concentrations based on local guidelines (Text S1) [24]. MMF (0.5 - 3 g day⁻¹) was administered based on body weight
138 (WT) and postoperative days (POD). This schedule was followed by oral prednisolone (80 mg day⁻¹) and the dosage was
139 gradually decreased by 10 mg day⁻¹ until reaching 20 mg day⁻¹ on day 10. The dosage was further tapered to 15, 10, and
140 5 mg day⁻¹ by months 1, 3, and 6, respectively.

141 **2.3 Bioassay**

142 Whole blood samples were treated with the anti-coagulant ethylene diamine tetraacetic acid and analysed with a
143 well-validated fluorescence polarisation immunoassay (FPIA) using an AxSYM® Abbott diagnostic system (Abbott
144 Diagnostics, Chicago, IL, USA) between July 2003 and April 2011, and a chemiluminescent microparticle immunoassay
145 (CMIA) using an Architect I2000 system between May 2011 and December 2016. For AxSYM, the limit of detection
146 (LOD) was 21.8 ng mL⁻¹, and the calibration range was 40 - 800 ng mL⁻¹; for CMIA, the LOD was 25 ng mL⁻¹, and the
147 calibration range was 30-1500 ng mL⁻¹.

148 The following formulae (Eq. 1) [25] was used to convert CMIA measured C₀ before modelling.

$$149 \text{AxSYM} = 0.87 \times \text{CMIA} + 25.84 \quad (1) [25]$$

150 where AxSYM represents the FPIA performed using an AxSYM analyser and CMIA represents the
151 chemiluminescent microparticle immunoassay.

152 2.4 Population Pharmacokinetic Model Development

153 Population PK analysis was performed using the NONMEM® software package (version 7.4; ICON Development
154 Solutions, Ellicott City, MD, USA), with Pirana® 2.9 as an interface for Perl Speaks NONMEM (PsN; version 4.9.0) and
155 R software (version 3.5.0, <http://www.r-project.org/>) [26]. The first-order conditional estimation method including η-e
156 interaction (FOCE-I) was used throughout the method-building procedure [27].

157 2.4.1 Base Model

158 To determine the potential influence of nonlinearity and the functional forms of covariates on model predictability,
159 four popPK models (linear compartmental model without incorporating daily dose, linear compartmental model
160 incorporating daily dose, theory-based nonlinear compartmental model, and nonlinear Michaelis-Menten (MM) empirical
161 model) were developed based on two structural models.

162 Since only the therapeutic drug monitor (TDM) C₀ and C₂ concentrations were available for analysis, one-
163 compartmental model with first-order absorption was used to describe CsA PKs in compartmental (CMT) models. The
164 model was parameterised in terms of apparent total clearance (CL/F), apparent volume of distribution (V/F), and the
165 absorption rate constant (K_a). K_a was fixed at 1.25 h⁻¹ based on literature values [11, 28].

166 A nonlinear MM empirical formula (Eq. 2) that quantified the overall relationship between daily dose and CsA
167 concentrations was used as a structural model to describe CsA PKs in the MM model [11].

$$168 \text{Daily Dose (mg)} = \frac{V_m(\text{mg}) \times C(\text{ng mL}^{-1})}{K_m(\text{ng mL}^{-1}) + C(\text{ng mL}^{-1})} \quad (2)$$

169 where V_m denotes the maximum dose rate (daily dose), K_m denotes the steady-state concentrations at half-maximal
170 dose rate and C represents the CsA C_0 or C_2 concentrations.

171 Between subject variability (BSV) was assumed to be log-normally distributed, and estimated for all parameters,
172 except K_a . Residual unexplained variability (RUV) was described by testing proportional, combined proportional, and
173 additive structures.

174 **2.4.2 Covariate Model**

175 The demographic and pathophysiological data, as well as concomitant medications (Table 1), were evaluated as
176 covariates. Information extracted from the medical records including body size, haematocrit, postoperative days (PODs),
177 CsA daily dose, and prednisolone dose were evaluated as the possible covariates of CsA PK. These covariates were
178 selected according to the previous report and clinical relevance [11].

179 As reviewed previously [11], weight was the most frequently identified covariate in the final models. Therefore, PK
180 disposition parameters were firstly related to body size based on allometric scaling theory [29, 30]. Body size was based
181 on fat free mass predicted from total body weight, height and sex (Text S2) [31].

182 The potential influence of nonlinearity and the functional forms of covariates on model predictability was tested
183 using four modelling strategies.

184 ***Strategy I: Linear compartmental model without incorporating daily dose***

185 As the influence of body size was considered, covariates other than body size were investigated empirically through
186 linear, piecewise linear, power, exponential or sigmoid functions in *Strategy I*. The concomitant medications were
187 evaluated as binary covariates by estimating the parameter fractional change in one group compared to the other.

188 ***Strategy II: Linear compartmental model incorporating daily dose***

189 Based on the result of *Strategy I*, CsA daily dose was empirically investigated on CL/F in this modelling strategy.

190 ***Strategy III: Theory-based nonlinear compartmental model***

191 The theory-based nonlinear compartmental model was developed based on well-accepted theoretical relationships.
192 CsA is extensively distributed in peripheral tissues and binds to erythrocytes and plasma proteins [3, 32, 33]. PK
193 disposition parameters were estimated from the model-predicted plasma concentrations (C_p) rather than measured whole-
194 blood concentrations (C_{wb}) under the assumption that the binding of CsA to plasma components is linear and the binding
195 to erythrocytes is nonlinear [32, 34].

196 Similar to descriptions by Størset *et al.* [35] and Van Erp *et al.* [36], the following equation was used to estimate CsA
197 C_p (Text S3) [37]:

$$198 \quad C_{wb} = (1 + 1.853 \times \text{HCT}) \times C_p \quad (3)$$

199 where C_{wb} is the whole-blood concentration, C_p is the plasma concentration, and HCT is the haematocrit level.

200 Therefore, all parameter estimates are expressed as plasma PK parameters in *Strategy III* and the model is capable
201 of predicting both whole-blood and plasma concentrations.

202 Corticosteroids are known inducers of CYP3A enzymes and P-glycoprotein in the small intestine and/or liver [19,
203 20] and, theoretically, lead to CsA CL/F alteration. Considering the hypothesis that tapering prednisolone dosage (Pred)
204 is the source of CsA nonlinearity, a sigmoid E_{max} model was implemented to describe the effect of prednisolone induction
205 on CsA PKs.

$$206 \quad \text{Ind} = \frac{\text{Pred}_{max} \times \text{Pred}^{\text{Hill}}}{\text{Pred}_{50} + \text{Pred}^{\text{Hill}}} \quad (4)$$

207 The term Ind in Eq. 4 represents the induction function relating to Pred. Pred_{max} is the maximum change in the PK
208 parameter of interest (i.e. F or CL), Pred_{50} is the prednisolone dose causing half maximum induction and Hill is the
209 sigmoid shape coefficient.

210 *Strategy IV: Nonlinear Michaelis-Menten empirical model*

211 After body size was included based on allometric scaling theory, the influence of other covariates on the MM
212 constant (K_m) were investigated empirically. As the CsA steady-state PK changed with time after transplantation, time
213 factors (A/θ , Eq. 5) were introduced to test whether the MM model with time-variant K_m was superior [12].

$$214 \quad \text{Daily Dose (mg)} = \frac{V_m(\text{mg}) \times C(\text{ng mL}^{-1})}{\frac{A}{\theta} \times K_m(\text{ng mL}^{-1}) + C(\text{ng mL}^{-1})} \quad (5)$$

215 Where A was POD if $1 \leq \text{POD} \leq \theta$, or A was θ if $\text{POD} > \theta$, V_m denotes the maximum dose rate (daily dose), K_m
216 denotes the steady-state concentrations at half-maximal dose rate and C represents the CsA C_0 or C_2 concentrations.

217 **2.4.3 Model Selection Criteria**

218 The log-likelihood ratio test was the main model selection tool. Change in objective function value (ΔOFV) was
219 calculated to assess the statistical significance of each covariate and to differentiate between theoretically equivalent
220 models [27]. Statistical significance levels of $p < 0.01$ and $p < 0.001$ (Chi-square distribution) were implemented in
221 forward inclusion and backward elimination procedures, respectively. Moreover, a clear pharmacological or biological
222 basis was also considered when covariates were included.

223 2.5 Model Evaluation

224 Fifty-two patients from the evaluation group were used to examine the predictability of the final four models.
225 Estimated population predictions (PREDS) were compared to the corresponding observations (OBS) using the
226 MAXEVAL=0 option (Eq. 6). The accuracy and imprecision of predictive performance were investigated using median
227 prediction error (MDPE) and median absolute prediction error (MAPE), respectively [38].

$$228 \quad PE (\%) = \left(\frac{PRED - OBS}{OBS} \right) \times 100 \quad (6)$$

229 The percentage of |PE| within 20% (F20) and 30% (F30) was also calculated. The model with lower MDPE and
230 MAPE values and fewer prediction errors (PE) beyond $\pm 20\%$ and $\pm 30\%$ was considered superior.

231 In addition to the prediction-based approaches described above, bootstrap [39] and simulation-based prediction-
232 corrected visual predictive checks (pcVPCs) [40] were conducted to evaluate candidate model predictability. Using Perl
233 modules, 2000 bootstrap datasets were generated by random sampling with replacement [41]. The final popPK model
234 was compared against each of these bootstrap datasets, and all model parameters were estimated.

235 The dataset was simulated 2000 times for pcVPCs. The 95% confidence intervals (CI) for the median and the 5th and
236 95th percentiles of the simulations at different times were calculated and compared to the observations, binning
237 automatically.

238 2.6 Nomenclature of targets and ligands

239 Key protein targets and ligands in this article are hyperlinked to corresponding entries in
240 <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY
241 [appropriate reference number], and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16
242 [appropriate reference number(s)].

243 3 Results

244 3.1 Patients

245 Demographic characteristics of the study population are presented in Table 1. A total of 2969 CsA whole-blood
246 measurements were collected from 173 patients after three days post-operation, including 1328 C₀ and 1641 C₂. There
247 was a median of 15 CsA observations per patient (range, 2 - 50). No concentrations below the lower quantification limit
248 were included in the analysis.

249 3.2 Population Pharmacokinetic Model Development

250 3.2.1 Base Model

251 To compare the potential influence of the structural model on model predictability, a one-compartmental model with
252 first-order absorption and MM empirical formula were used as a structural model to describe CsA PKs. Based on the
253 OFV and the distribution of residuals in the diagnostic plots of the base model, an exponential error model and additive
254 error model were selected to model the random variability for three CMT models and the MM model, respectively.

255 3.2.2 Covariate Model

256 The final model parameter estimate results are shown in [Table 2](#). When covariates were included in univariate
257 analysis, neither bodyweight nor other demographic variables provided a significant drop in the OFV ($P < 0.01$).

258 The influence of patients' body size on CsA disposition was best described by allometric scaling based on fat free
259 mass rather than total body weight for all the PK disposition parameters. After body size, the effect of HCT on CsA
260 clearance was investigated. The OFV substantially declined as HCT was included. *Strategy III*, which accounted for
261 differences in CsA whole-blood concentrations due to haematocrit variation via estimation of C_p , was superior to *Strategy*
262 *I and Strategy II* that estimated CsA PK parameters based on whole-blood concentrations alone (Δ OFV -140.4 vs -
263 123.6, $P < 0.001$).

264 Prednisolone dose had no significant influence on CL/F when it was investigated empirically in *Strategy I* and
265 *Strategy II*. As prednisolone dosage tapered dramatically in the initial stage of transplantation, the theory-based
266 *Strategy III* tested the effect of prednisolone on F based on the hypothesis that the high prednisolone dosage may
267 influence CsA absorption nonlinearly. Therefore, a sigmoid E_{max} model describing an effect of prednisolone dose on F
268 (Eq. 4) reduced the OFV by -54.9 ($P < 0.001$) and was superior to the linear model (Δ OFV -40.8). However, the relative
269 standard error estimated for $Pred_{50}$ was 136.9%, indicating a sparse sampling design that was unable to yield reliable
270 estimates of the nonlinear prednisolone effect on CsA absorption. Thus, the coefficient was introduced to describe this
271 effect. The CL/F of patients receiving combined immunosuppressive therapy in the first 15 PODs was 8% higher than
272 the following times (Δ OFV -40.5, Eq. 9).

273 A significant increase (119.7%) in CL/F was seen as the CsA daily dose (DD) increased from 50 to 600 mg (Δ OFV
274 -22.9, $P < 0.001$) in *Strategy III*, indicating a nonlinear relationship between DD and CL/F . Based on *Strategy I*, DD
275 was also involved in *Strategy II* (Δ OFV -77.9, $P < 0.001$), indicating a significant model improvement. In addition to
276 these covariate effects, CL/F was found to significantly increase with POD in an exponential function for all three CMT
277 models.

278 For nonlinear *Strategy IV*, as the CsA oral clearance seemed to change with time, the influence of POD on K_m was
 279 included both for C_0 ($\Delta\text{OFV} -611.6, P < 0.001$) and C_2 ($\Delta\text{OFV} -743.3, P < 0.001$). Then, time factors (A/θ , Eq. 12) were
 280 introduced to test whether the MM model with time-variant K_m was superior. The weighted residuals (y-axis) showed a
 281 clear trend when plotted against the PODs before time factors were added (Fig. S1, left panel). This trend was resolved
 282 with the time-variant model (Fig. S1, right panel).

283 In final models, all retained covariates caused a significant increase in OFV upon removal. The following were
 284 determined to be the final models with CL/F or K_m covariates.

285 *Strategy I*: $CL/F = 25.2 \times (\text{FFM}/50)^{0.75} \times (\text{HCT}/30)^{-0.404} \times e^{0.00344 \times (\text{POD}/30)}$ (7)

286 *Strategy II*: $CL/F = 24.6 \times (\text{FFM}/50)^{0.75} \times (\text{HCT}/30)^{-0.354} \times e^{0.0121 \times (\text{POD}/30)} \times (\text{DD}/275)^{0.278}$ (8)

287 *Strategy III*: $CL/F = 14.3 \times (\text{FFM}/50)^{0.75} \times e^{0.0119 \times (\text{POD}/30)} \times \frac{3.4 \times \text{DD}}{72.8 + \text{DD}}$
 288 $(\times 1.08, \text{ if } \text{PD} > 0 \text{ and } \text{POD} \leq 15)$ (9)

289 *Strategy IV*: $K_m \text{ for } C_0 = 45.3 \times (\text{FFM}/50)^{0.75} \times (\text{POD}/30)^{0.336}$ (10)

290 $K_m \text{ for } C_2 = 182 \times (\text{FFM}/50)^{0.75} \times (\text{POD}/30)^{0.309}$ (11)

291 $\text{Daily Dose (mg)} = \frac{V_m(\text{mg}) \times C(\text{ng mL}^{-1})}{\frac{A}{90} \times K_m(\text{ng mL}^{-1}) + C(\text{ng mL}^{-1})}$ (12)

292 Where A was POD if $1 \leq \text{POD} \leq 90$, or A was 90 if $\text{POD} > 90$

293 in which the influence scopes were adjusted by their respective median values determined from the dataset.

294 The estimated PK parameters of the final models were comparable with those of previously published models for
 295 CsA in renal transplant recipients. Based on a standard haematocrit value of 30%, the corresponding whole blood apparent
 296 clearance of *Strategies I-III* were 25.2 h^{-1} , 24.6 h^{-1} , and 25.1 h^{-1} , respectively. The MM constant (K_m) was 45.3 ng/ml
 297 for C_0 and 182 ng/ml for C_2 one month after transplantation, respectively.

298 3.3 Model evaluation

299 The goodness-of-fit plots for the base and four final models are presented in Fig. S2. Compared to the base model,
 300 the final models were greatly improved and showed no structural bias. pcVPCs of the four final models are depicted in
 301 Fig. 1. The simulated data corresponded well with the observed data, indicating the lack of significant model
 302 misspecifications. Consistently, bootstrap parameter estimates closely matched the mean estimates from the population
 303 model, confirming model stability (Table S1).

304 The F_{30} of the nonlinear MM model showed a remarkable improvement over the other three CMT models, regardless
 305 of whether the base (63.4% versus 52.4%) or final (71.1% versus 56.2%, 58.2% and 59.8%) models were used (Fig. 2

306 and Table 3). The theory-based nonlinear model performed better than the other two CMT models. The predictability
307 improved as nonlinearity was considered.

308 **4 Discussion**

309 Empirical investigation of nearly 20 popPK models developed for CsA to aid in the prediction of initial and
310 maintained doses in kidney transplant recipients revealed inconsistent covariate identification. According to our previous
311 investigation [11], the predictability of these empirical CMT models was not precise enough when extrapolated to another
312 clinical centre. Most of these models had not fully considered CsA nonlinear property in modelling processes.

313 The current study developed four different modelling strategy-based popPK models and compared predictive
314 performances to determine the potential influence of nonlinearity and the functional forms of covariates on model
315 predictability. The conclusion that predictability improved as nonlinearity was considered in the CsA modelling process
316 was demonstrated in this large cohort study. Incorporating covariates based on a fundamental understanding of PK
317 processes can help to improve model predictability. The predictive performance of the nonlinear MM empirical model
318 was much better than that of the compartmental models, indicating that other sources of CsA PK nonlinearity should be
319 considered in further analyses.

320 Unlike empirical covariate selection, theory-based covariate selection allows the incorporation of relationships
321 linking parameters and covariates based on a fundamental understanding of PK processes rather than on the available data
322 alone [22]. In contrast to the empirical approaches in previous studies, covariates in *Strategy III* were investigated based
323 on theoretical mechanisms, and the potential mechanisms for CsA PK nonlinearity were determined by popPK analysis.
324 Allometric scaling to fat free mass, saturated distribution into red blood cells, and the influence of CsA daily dose on
325 metabolism were all incorporated into the final model based on the fundamental understanding of PK processes. The
326 change in bioavailability caused by tapering the prednisolone dose in the initial stage of transplantation, other
327 pathophysiological factors, and drug-drug interactions were also investigated. Most of these factors contributed to CsA
328 PK nonlinearity.

329 The influence of haematocrit on the CsA PK process was primarily considered because approximately 58% of
330 circulating CsA was bound to red blood cells [42]. According to the work of Lemaire *et al.* [34] and Legg *et al.* [32],
331 CsA binding to plasma components is linear, while binding to erythrocytes is nonlinear. Haematocrit is reduced in
332 transplant patients and occurs at a lower level in the early postoperative period [42]. To reduce the confounding effect
333 of haematocrit variability in predicting CsA concentrations, we hypothesised that the plasma concentration is
334 proportional to the unbound CsA concentration, and the PK parameters of *Strategy III* are established from implicit

335 plasma concentrations rather than whole blood concentrations. Based on a standard haematocrit value of 30%, the
336 corresponding whole-blood apparent clearance (CL_{wb}/F) was 25.1 l h^{-1} . This is comparable to previously published values
337 ($17.0\text{-}50.4 \text{ l h}^{-1}$) [11] and consistent with the results of the linear compartmental model [43].

338 To date, almost all published CsA popPK models determined the haematocrit effect on CsA PK processes through
339 an empirical approach, such as *Strategies I* and *II*, and only two studies retained this covariate in the final model
340 [44, 45]. This phenomenon was inconsistent with the CsA distribution mechanism, which may influence model
341 predictability. Furthermore, CsA TDM is based on whole-blood concentrations, which have a very variable relationship
342 with unbound concentrations. The unbound concentration is considered more closely related to accurately determining
343 efficacy or side effects [46]. Therefore, this should be the focus of future studies.

344 The obvious improvement in predictability observed when the daily dose was incorporated (*Strategy I* versus
345 *Strategy II*) illustrated apparent clearance dose dependency. *In vitro*, CsA is a moderately strong CYP3A4- and strong
346 P-gp inhibitor [14, 15, 47]. Based on formation of the M1 metabolite as a CYP3A4 probe, hepatic CYP3A4 activity
347 decreases by up to 26% in the presence of CsA [48]. The inhibitory effects of CsA on CYP3A4 and P-gp can lead to
348 autoinhibition and dose-dependent PKs, which may also contribute to CsA nonlinearity [47, 49]. Therefore, in *Strategy*
349 *III*, the CsA daily dose was included nonlinearly; CL/F increased from 12.7 l h^{-1} to 27.9 l h^{-1} as the CsA daily dose
350 changed from 50 mg day^{-1} to 600 mg day^{-1} , demonstrating that increasing the CsA dose produces a disproportional
351 increase in CsA exposure.

352 In healthy volunteers administered a single oral dose, the CsA PK is normally considered linear [8]. However,
353 physiology disorders, co-administrated drugs, and other intrinsic factors in clinical testing may influence CsA PK
354 behaviour. In the present analysis, the bioavailability change caused by tapering the prednisolone dose in the early PODs
355 was considered by initially incorporating the effect of prednisolone dose on F nonlinearly. However, the sparse sampling
356 design could not yield reliable estimates of the nonlinear prednisolone effect on CsA absorption. An 8% clearance
357 increase was observed when a higher steroid dosage was received in the initial stage of transplantation; this phenomenon
358 should be further elucidated. Variability from concomitant calcium channel blockers was considered but no significant
359 effect was found.

360 According to previous findings, WT and POD are the most recognised covariates in empirical building studies [11].
361 WT-relevant factors were considered in the present study and fat free mass was included. It is reasonable to accept fat-
362 free mass as a predictor of CsA clearance because fat mass is not expected to directly influence metabolic capacity [25].
363 POD, as a surrogate for many time-dependent factors, was included in the final model. Some factors that are known to

364 systematically change with POD, such as HCT and DD, were also investigated. Other currently unknown POD-related
365 factors should be explored in future studies.

366 The retrospective observational study design did not allow confirmation of whether patients adhered to their
367 prescribed dosage regimen, and no intensive sampling was available in this study. The sparse sampling design could not
368 yield reliable estimates of the nonlinear prednisolone effect on CsA absorption.

369 By comparing the predictive performance of four popPK models based on different modelling strategies, we found
370 that incorporating nonlinear properties is likely to be a promising approach for improving CsA model predictability.
371 Saturated distribution into red blood cells, and auto-inhibition that arose from the inhibitory effects of CsA on *CYP3A4/P-*
372 *gp* and CsA-prednisolone drug interaction may be the main sources of CsA PK nonlinearity.

373 **5 Compliance with Ethical Standards**

374 **Funding:**

375 This work was supported in part by grants from the National Natural Science Foundation of China (No. 81 573 505
376 and 81 072 702), the “2016 Key Clinical Program of Clinical Pharmacy”, and “Weak Discipline Construction Project”
377 (No. 2016ZB0301-01) of Shanghai Municipal Health and Family Planning Commission.

378 **Conflict of interest:**

379 There are no financial relationships with any organisations that might have an interest in the submitted work in the
380 previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work. The
381 other authors have no conflicts of interest to declare.

382 **Ethical Approval:**

383 All procedures involving human participants were in accordance with the ethical standards of the institutional and/or
384 national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical
385 standards.

386 **6 Contributors**

387 JJM and ZJ participated in the research design. XYQ, MKZ and MZ helped acquire the evaluated data. JJM
388 performed the research and analysed the data. JJM and ZJ drafted the manuscript, which was revised and approved by all
389 the authors. There are no other relationships or activities that could appear to have influenced the submitted work.

390 **7 Acknowledgments**

391 The authors are grateful to Dr. Chen-Yan Zhao of the University of Uppsala for her invaluable advice, and Han-
392 Chao Chen of Huashan Hospital for his support during data editing.

393

394 **8 Data availability statement**

395 The data that support the findings of this study are available from the corresponding author upon reasonable request.

396 **9 References**

- 397 1. Fahr A. Cyclosporin clinical pharmacokinetics. *Clin Pharmacokinet* 1993; 24: 472-95.
- 398 2. Shaw LM, Bowers L, Demers L, Freeman D, Moyer T, Sanghvi A, et al. Critical issues in cyclosporine monitoring:
399 report of the Task Force on Cyclosporine Monitoring. *Clin Chem* 1987; 33: 1269-88.
- 400 3. Legg B, Gupta SK, Rowland M, Johnson RW, Solomon LR. Cyclosporin: pharmacokinetics and detailed studies of
401 plasma and erythrocyte binding during intravenous and oral administration. *Eur J Clin Pharmacol* 1988; 34: 451-60.
- 402 4. Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, et al. In vitro metabolism of cyclosporine A by human
403 kidney CYP3A5. *Biochem Pharmacol* 2004; 68: 1889-902.
- 404 5. Akhlaghi F, Dostalek M, Falck P, Mendonza AE, Amundsen R, Gohh RY, et al. The Concentration of Cyclosporine
405 Metabolites Is Significantly Lower in Kidney Transplant Recipients With Diabetes Mellitus. *Therapeutic Drug Monitoring*
406 2012; 34: 38-45.
- 407 6. Venkataramanan R, Starzl TE, Yang S, Burckart GJ, Ptachcinski RJ, Shaw BW, et al. Biliary Excretion of Cyclosporine
408 in Liver Transplant Patients. *Transplant Proc* 1985; 17: 286-9.
- 409 7. Reymond JP, Steimer JL, Niederberger W. On the dose dependency of cyclosporin A absorption and disposition in
410 healthy volunteers. *J Pharmacokinet Biopharm* 1988; 16: 331-53.
- 411 8. Pollard SG, Lear PA, Ready AR, Moore RH, Johnson RW. Comparison of microemulsion and conventional
412 formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal
413 Study Group. *Transplantation* 1999; 68: 1325-31.
- 414 9. Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporine
415 pharmacokinetics from a microemulsion formulation. *Pharm Res* 1994; 11: 301-4.
- 416 10. Grillo JA, Zhao P, Bullock J, Booth BP, Lu M, Robie-Suh K, et al. Utility of a physiologically-based pharmacokinetic
417 (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban
418 during the drug review process: implications for clinical practice. *Biopharm Drug Dispos* 2012; 33: 99-110.
- 419 11. Mao JJ, Jiao Z, Yun HY, Zhao CY, Chen HC, Qiu XY, et al. External evaluation of population pharmacokinetic models
420 for ciclosporin in adult renal transplant recipients. *Br J Clin Pharmacol* 2018; 84: 153-71.
- 421 12. Grevel J, Post BK, Kahan BD. Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a
422 population analysis in kidney transplant patients. *Clin Pharmacol Ther* 1993; 53: 651-60.
- 423 13. Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.
424 *Drugs* 2003; 63: 367-78.

- 425 14. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for
426 drug-drug interaction between cerivastatin and cyclosporin A. *J Pharmacol Exp Ther* 2003; 304: 610-6.
- 427 15. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus
428 oral drug delivery. *Adv Drug Deliv Rev* 1997; 27: 201-14.
- 429 16. Tamai I, Safa AR. Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in
430 multidrug-resistant cells. *J Biol Chem* 1990; 265: 16509-13.
- 431 17. Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB. PharmGKB summary: cyclosporine and
432 tacrolimus pathways. *Pharmacogenet Genomics* 2013; 23: 563-85.
- 433 18. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug
434 metabolism and pharmacogenetics. *Curr Drug Metab* 2005; 6: 369-83.
- 435 19. Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone induces pregnane X receptor and
436 retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X
437 receptor activators. *Mol Pharmacol* 2000; 58: 361-72.
- 438 20. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. Dual effect of dexamethasone on
439 CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor.
440 *Eur J Biochem* 2001; 268: 6346-58.
- 441 21. Han K, Pillai VC, Venkataramanan R. Population pharmacokinetics of cyclosporine in transplant recipients. *AAPS J*
442 2013; 15: 901-12.
- 443 22. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-
444 pharmacodynamic (PK-PD) modeling in translational drug research. *Trends Pharmacol Sci* 2008; 29: 186-91.
- 445 23. Zhao CY, Jiao Z, Mao JJ, Qiu XY. External evaluation of published population pharmacokinetic models of tacrolimus
446 in adult renal transplant recipients. *Br J Clin Pharmacol* 2016; 81: 891-907.
- 447 24. Shi BY Yuan M. Guidelines for immunosuppressive therapy in Chinese renal transplant recipients. *Organ*
448 *Transplantation* 2016; 7: 327-31.
- 449 25. Serdarevic N, Zunic L. Comparison of architect I 2000 for determination of cyclosporine with axsym. *Acta Inform*
450 *Med* 2012; 20: 214-7.
- 451 26. Keizer RJ, Karlsson MO, Hooker A. Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and
452 Xpose. *CPT Pharmacometrics Syst Pharmacol* 2013; 2: e50.
- 453 27. Beal SL, Boeckmann A, Bauer RJ. NONMEM User's Guides. Ellicott City, MD, USA: Icon Development Solutions 1989-
454 2010.

- 455 28. Chen B, Zhang W, Gu Z, Li J, Zhang Y, Cai W. Population pharmacokinetic study of cyclosporine in Chinese renal
456 transplant recipients. *Eur J Clin Pharmacol* 2011; 67: 601-12.
- 457 29. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. *Science* 1997;
458 276: 122-6.
- 459 30. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans.
460 *Drug Metab Pharmacokinet* 2009; 24: 25-36.
- 461 31. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. *Clin*
462 *Pharmacokinet* 2005; 44: 1051-65.
- 463 32. Legg B, Rowland M. Cyclosporin: measurement of fraction unbound in plasma. *J Pharm Pharmacol* 1987; 39: 599-
464 603.
- 465 33. Sgoutas D, MacMahon W, Love A, Jerkunica I. Interaction of cyclosporin A with human lipoproteins. *J Pharm*
466 *Pharmacol* 1986; 38: 583-8.
- 467 34. Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin
468 A in the blood. *J Pharm Pharmacol* 1982; 34: 715-8.
- 469 35. Storset E, Holford N, Hennig S, Bergmann TK, Bergan S, Bremer S, et al. Improved prediction of tacrolimus
470 concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. *Br J Clin Pharmacol*
471 2014; 78: 509-23.
- 472 36. van Erp NP, van Herpen CM, de Wit D, Willemsen A, Burger DM, Huitema AD, et al. A Semi-Physiological Population
473 Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients.
474 *Clin Pharmacokinet* 2016; 55: 1447-56.
- 475 37. Legg B, Rowland M. Cyclosporin: erythrocyte binding and an examination of its use to estimate unbound
476 concentration. *Ther Drug Monit* 1988; 10: 16-9.
- 477 38. Sheiner LB, Beal SL. Some Suggestions for Measuring Predictive Performance. *Journal of Pharmacokinetics and*
478 *Biopharmaceutics* 1981; 9: 503-12.
- 479 39. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV. Model appropriateness and population pharmacokinetic
480 modeling. *J Clin Pharmacol* 2003; 43: 610-23.
- 481 40. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing
482 nonlinear mixed-effects models. *AAPS J* 2011; 13: 143-51.
- 483 41. Ette EI. Stability and performance of a population pharmacokinetic model. *J Clin Pharmacol* 1997; 37: 486-95.

- 484 42. Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV. Long-term cyclosporine pharmacokinetic changes in renal
485 transplant recipients: effects of binding and metabolism. *Clin Pharmacol Ther* 1989; 45: 41-8.
- 486 43. Okada A, Ushigome H, Kanamori M, Morikochi A, Kasai H, Kosaka T, et al. Population pharmacokinetics of
487 cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center. *Eur J Clin Pharmacol*
488 2017; 73: 1111-9.
- 489 44. Wu KH, Cui YM, Guo JF, Zhou Y, Zhai SD, Cui FD, et al. Population pharmacokinetics of cyclosporine in clinical renal
490 transplant patients. *Drug Metab Dispos* 2005; 33: 1268-75.
- 491 45. Zhou H, Zhang RL, Li ZD, Li J. Population pharmacokinetics study of cyclosporine A in renal transplantation patients.
492 *Chinese Pharmacological Bulletin* 2011; 27: 431-5.
- 493 46. Rowland M. Plasma protein binding and therapeutic drug monitoring. *Ther Drug Monit* 1980; 2: 29-37.
- 494 47. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma
495 concentrations of repaglinide. *Clin Pharmacol Ther* 2005; 78: 388-99.
- 496 48. Gertz M, Cartwright CM, Hobbs MJ, Kenworthy KE, Rowland M, Houston JB, et al. Cyclosporine inhibition of hepatic
497 and intestinal CYP3A4, uptake and efflux transporters: Application of PBPK Modeling in the assessment of drug-drug
498 interaction potential. *Pharmaceutical Research* 2013; 30: 761-80.
- 499 49. Fricker G, Drewe J, Huwylar J, Gutmann H, Beglinger C. Relevance of p-glycoprotein for the enteral absorption of
500 cyclosporin A: in vitro-in vivo correlation. *Br J Pharmacol* 1996; 118: 1841-7.
- 501

502 **Figure Legends**

503 **Fig. 1** Prediction-corrected visual predictive checks (pcVPCs) stratified on postoperative days (PODs) for four established
504 final models, based on 2000 simulations. The *red solid line* connects median observed values per bin, the *red dashed lines*
505 connect the 5th and 95th percentiles of the observations. The *blue areas* are the 95 % confidence interval of the 5th and 95th
506 percentiles. The *red area* indicates the confidence interval of the median. **a** pcVPC of linear compartmental model without
507 incorporating daily dose, **b** pcVPC of linear compartmental model incorporating daily dose, **c** pcVPC of theory-based
508 nonlinear compartmental model, **d** pcVPC of nonlinear Michaelis-Menten empirical model for pre-dose concentrations,
509 **e** pcVPC of nonlinear Michaelis-Menten empirical model for 2-h post-dose concentrations.

510

511 **Fig. 2** Box plots of the prediction error (PE%) for the four established final models. *Black solid lines* and *blue dotted lines*
512 are reference lines indicating PE% of 0% and $\pm 20\%$, respectively. *CMT* linear compartmental model, *DD* cyclosporine
513 daily dose, *MM* Michaelis-Menten model, *N-CMT* nonlinear compartmental model. Models with an asterisk (*) were
514 developed based on the Michaelis-Menten model.

Table 1 Patients demographics used to develop and evaluate population model

Characteristics	Model development dataset		Model Evaluation dataset	
	Number or Mean \pm SD	Median (Range)	Number or Mean \pm SD	Median (Range)
No. of patients (Male/Female) ^a	121 (83/38)	/	52 (29/23)	/
No. of Samples (C ₀ /C ₂) ^b	2037 (908/1129)	/	932 (420/512)	/
Age (years)	39.3 \pm 9.6	40 (18-59)	40.9 \pm 10.0	41 (21-59)
Height (cm)	168.0 \pm 8.0	170.0 (152.0-188.0)	167.0 \pm 7.0	167.0 (150.0-184.0)
Weight (kg)	61.5 \pm 11.3	60.0 (40.0-95.0)	59.1 \pm 10.0	59.8 (39.4-90.0)
Post-operation days	145.0 \pm 242.2	24 (3-1075)	170.5 \pm 253.8	31.5 (3-1095)
CsA daily dose (mg day ⁻¹)	284.3 \pm 90.1	300 (50-600)	257.8 \pm 92.7	275.0 (50-450)
Prednisolone dose (mg day ⁻¹)	19.2 \pm 16.1	20 (0-80)	17.8 \pm 16.0	20 (0-80)
C ₀ (ng ml ⁻¹)	173.9 \pm 93.1	155.6 (29.6-974.6)	174.2 \pm 82.6	167.2 (30.0-470.6)
C ₂ (ng ml ⁻¹)	836.9 \pm 367.5	805.4 (34.6-2572.8)	827.4 \pm 385.3	775.8 (74.2-2161.5)
Total Bilirubin (μ mol L ⁻¹)	10.3 \pm 5.9	9.0 (1.0-60.3)	10.8 \pm 5.9	9.2 (1.0-40.9)
Haematocrit (%)	31.4 \pm 7.4	30.7 (10.5-60.5)	32.1 \pm 7.0	31.9 (15.9-50.1)
Alanine aminotransferase (U L ⁻¹)	33.0 \pm 42.3	21.0 (4.0-420.0)	30.4 \pm 31.8	22.0 (5.0-394.0)
Aspartate transferase (U L ⁻¹)	23.9 \pm 18.9	19.0 (1.0-279.0)	22.0 \pm 14.4	19.0 (6.0-217.0)
Albumin (g L ⁻¹)	36.1 \pm 6.3	36.0 (20.0-52.0)	37.6 \pm 6.5	37.4 (22.0-51.0)
Total protein (g L ⁻¹)	62.4 \pm 8.5	62.0 (41.0-87.0)	64.3 \pm 8.9	64.0 (43.0-88.0)
Serum Creatinine (μ mol L ⁻¹)	132.3 \pm 97.6	109.0 (29.0-1052.0)	119.9 \pm 64.2	107.0 (49.0-671.0)
Creatinine Clearance (ml min ⁻¹) ^c	66.3 \pm 24.9	65.5 (6.2-241.5)	63.5 \pm 19.0	63.5 (8.6-132.7)
Concomitant calcium channel blocker ^a				
Felodipine	71	/	25	/
Nifedipine	52	/	14	/
Perdipine	17	/	3	/

C₀, pre-dose concentration; C₂, 2-hour post-dose concentration

^aData are expressed as number of patients

^bData are expressed as number of samples

^c Calculated following the Cockcroft-Gault formula: $Ccr = [(140 - \text{Age}(\text{year})) \times \text{WT}(\text{kg})] / (0.818 \times \text{Scr} (\mu\text{mol L}^{-1})) \times (0.85 \text{ for female})$

Table 2 Parameter estimates of four popPK models based on different modelling strategies

Parameters	<i>Strategy I:</i>	<i>Strategy II:</i>	<i>Strategy III:</i>	<i>Strategy IV:</i>	
	Linear compartmental model without incorporating DD	Linear compartmental model incorporating DD	Theory-based nonlinear compartmental model ^a	Nonlinear MM empirical model	
				C ₀	C ₂
Objective function value	32858.4	32706.3	32617.4	11331.9	14132.7
K _a (h ⁻¹)	1.25 (fixed)	1.25 (fixed)	1.25 (fixed)	/	/
CL/ <i>F</i> (L h ⁻¹)	25.2 (2.0)	24.6 (1.8)	14.3 (2.5)	/	/
V·(FFM/50)/ <i>F</i> (L)	162.0 (2.8)	162.0 (2.8)	254.0 (2.7)	/	/
K _m (ng ml ⁻¹)	/	/	/	45.3 (30.9)	182.0 (20.8)
V _m (mg day ⁻¹)	/	/	/	334.0 (1.7)	329.0 (1.7)
Covariate effect on CL/K _m ^c					
HCT	-0.404 (12.6)	-0.354 (14.8)	/	/	/
POD	0.00344 (44.8)	0.0121 (16.4)	0.0119 (16.1)	0.336 (38.7)	0.309 (23.1)
DD	/	0.278 (19.3)	3.4 (4.2) ^b	/	/
	/	/	72.8 (26.6) ^b	/	/
PD	/	/	1.08 (1.2)	/	/
ω _{CL/<i>F</i>} (%) / ω _{K_m} (%) ^c	22.8 (10.4)	19.9 (11.4)	19.1 (12.0)	107.2 (11.8)	103.4 (10.5)
η - shrinkage (%)	6.3	7.7	7.9	24.0	18.4
σ (%/ng ml ⁻¹) ^d	34.5 (3.5)	34.1 (3.2)	33.8 (3.2)	32.9 (5.8)	35.2 (4.7)
ε - shrinkage (%)	3.8	3.7	3.6	9.4	8.2

Estimates are expressed as estimate (% standard error)

C₀, pre-dose concentration; C₂, 2-h post-dose concentration; CL/*F*, apparent clearance; DD, CsA daily dose; *F*, the bioavailability relative to 1; FFM, fat-free mass; HCT, haematocrit; K_a, absorption rate constant; K_m, steady-state concentrations at half-maximal dose rate; MM, Michaelis-Menten; PD, prednisolone daily dose; POD, postoperative days; V/*F*, apparent volume of distribution; V_m, maximum daily dose rate; ω, between subject variability; σ, residual variability

^a The parameters estimated are expressed as plasma pharmacokinetic parameters in *Strategy III*

^b 3.4 is the maximum change in CL with increasing CsA daily dose; 72.8mg is the CsA daily dose with half maximum on CL

^c The parameters estimated in *Strategy I* and *II* are the results on apparent whole blood clearance; the parameters estimated in *Strategy III* are the results on apparent plasma clearance; the parameters estimated in *Strategy IV* are the results on K_m

^d Exponential error model is selected for *Strategies I-III* and additive error model is selected for *Strategy IV*

Table 3 A summary of external evaluation

Candidate models	MDPE (%)	MAPE (%)	F₂₀ (%)	F₃₀ (%)
Linear compartmental base model	-6.1%	28.7%	35.5%	52.4%
Nonlinear MM base model	9.2%	20.3%	48.9%	63.4%
Linear compartmental model without incorporating DD (<i>Strategy I</i>)	-3.9%	26.1%	40.6%	56.2%
Linear compartmental model incorporating DD (<i>Strategy II</i>)	-0.5%	24.8%	40.5%	58.2%
Theory-based nonlinear compartmental model (<i>Strategy III</i>)	-1.4%	23.9%	42.3%	59.8%
Nonlinear MM empirical model (<i>Strategy IV</i>)	6.5%	16.2%	59.4%	71.1%

DD, Cyclosporine daily dose; F₂₀ and F₃₀, the percentage of prediction error $\leq \pm 20\%$ and $\pm 30\%$, respectively; MAPE, median absolute prediction error; MDPE, median prediction error; MM, Michaelis-Menten




Fig. 1 Prediction-corrected visual predictive checks (pcVPCs) stratified on postoperative days (PODs) for four established final models, based on 2000 simulations. The *red solid line* connects median observed values per bin, the *red dashed lines* connect the 5th and 95th percentiles of the observations. The *blue areas* are the 95 % confidence interval of the 5th and 95th percentiles. The *red area* indicates the confidence interval of the median. **a** pcVPC of linear compartmental model without incorporating daily dose, **b** pcVPC of linear compartmental model incorporating daily dose, **c** pcVPC of theory-based nonlinear compartmental model, **d** pcVPC of nonlinear Michaelis-Menten empirical model for pre-dose concentrations, **e** pcVPC of nonlinear Michaelis-Menten empirical model for 2-h post-dose concentrations.

177x177mm (300 x 300 DPI)




Fig. 1 Prediction-corrected visual predictive checks (pcVPCs) stratified on postoperative days (PODs) for four established final models, based on 2000 simulations. The *red solid line* connects median observed values per bin, the *red dashed lines* connect the 5th and 95th percentiles of the observations. The *blue areas* are the 95 % confidence interval of the 5th and 95th percentiles. The *red area* indicates the confidence interval of the median. **a** pcVPC of linear compartmental model without incorporating daily dose, **b** pcVPC of linear compartmental model incorporating daily dose, **c** pcVPC of theory-based nonlinear compartmental model, **d** pcVPC of nonlinear Michaelis-Menten empirical model for pre-dose concentrations, **e** pcVPC of nonlinear Michaelis-Menten empirical model for 2-h post-dose concentrations.

177x177mm (300 x 300 DPI)




Fig. 1 Prediction-corrected visual predictive checks (pcVPCs) stratified on postoperative days (PODs) for four established final models, based on 2000 simulations. The *red solid line* connects median observed values per bin, the *red dashed lines* connect the 5th and 95th percentiles of the observations. The *blue areas* are the 95 % confidence interval of the 5th and 95th percentiles. The *red area* indicates the confidence interval of the median. **a** pcVPC of linear compartmental model without incorporating daily dose, **b** pcVPC of linear compartmental model incorporating daily dose, **c** pcVPC of theory-based nonlinear compartmental model, **d** pcVPC of nonlinear Michaelis-Menten empirical model for pre-dose concentrations, **e** pcVPC of nonlinear Michaelis-Menten empirical model for 2-h post-dose concentrations.

177x177mm (300 x 300 DPI)




Fig. 1 Prediction-corrected visual predictive checks (pcVPCs) stratified on postoperative days (PODs) for four established final models, based on 2000 simulations. The *red solid line* connects median observed values per bin, the *red dashed lines* connect the 5th and 95th percentiles of the observations. The *blue areas* are the 95 % confidence interval of the 5th and 95th percentiles. The *red area* indicates the confidence interval of the median. **a** pcVPC of linear compartmental model without incorporating daily dose, **b** pcVPC of linear compartmental model incorporating daily dose, **c** pcVPC of theory-based nonlinear compartmental model, **d** pcVPC of nonlinear Michaelis-Menten empirical model for pre-dose concentrations, **e** pcVPC of nonlinear Michaelis-Menten empirical model for 2-h post-dose concentrations.

177x177mm (300 x 300 DPI)




Fig. 1 Prediction-corrected visual predictive checks (pcVPCs) stratified on postoperative days (PODs) for four established final models, based on 2000 simulations. The *red solid line* connects median observed values per bin, the *red dashed lines* connect the 5th and 95th percentiles of the observations. The *blue areas* are the 95 % confidence interval of the 5th and 95th percentiles. The *red area* indicates the confidence interval of the median. **a** pcVPC of linear compartmental model without incorporating daily dose, **b** pcVPC of linear compartmental model incorporating daily dose, **c** pcVPC of theory-based nonlinear compartmental model, **d** pcVPC of nonlinear Michaelis-Menten empirical model for pre-dose concentrations, **e** pcVPC of nonlinear Michaelis-Menten empirical model for 2-h post-dose concentrations.

177x177mm (300 x 300 DPI)




Fig. 2 Box plots of the prediction error (PE%) for the four established final models. *Black solid lines* and *blue dotted lines* are reference lines indicating PE% of 0% and $\pm 20\%$, respectively. *CMT* linear compartmental model, *DD* cyclosporine daily dose, *MM* Michaelis-Menten model, *N-CMT* nonlinear compartmental model. Models with an asterisk (*) were developed based on the Michaelis-Menten model.

181x94mm (300 x 300 DPI)

1 **Supporting information**

2 Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

3 **Supplementary Text S1** Target concentrations of CsA therapeutic monitoring

4 **Supplementary Text S2** The semi-mechanistic model used to predict fat-free mass

5 **Supplementary Text S3** The derivation process of formula used to predict CsA plasma concentrations

6

7 **Table S1** A summary of parameters estimated by four final models using 2,000 bootstrap runs

8

9 **Figure S1** Residual plot of the time-invariant (*left panel*) and the time-variant (*right panel*) Michaelis-Menten model.

10 The conditional weighted residuals (CWRES) are plotted against the postoperative days. **a** the results of
11 Michaelis-Menten model for pre-dose concentrations, **b** the results of Michaelis-Menten model for 2-h post-dose
12 concentrations. *Red lines* represents the LOESS smoothing.

13

14 **Figure S2 a-h** Goodness-of-fit plots for base model and four final models. **a,e** population prediction versus observation,
15 **b,f** individual prediction versus observation, **c,g** population prediction versus conditional weighted residuals (CWRES),
16 **d,h** postoperative days versus CWRES. **a-d** the results of compartmental models, **e-h** the results of Michaelis-Menten
17 models. *Solid lines* in **a,b,e,f** represent lines of identity, *Red lines* represent LOESS smoothing. *CMT* compartmental
18 model, *CMT+DD* linear compartmental model incorporating daily dose, *N-CMT* theory-based nonlinear compartmental
19 model, *MM-C₀* nonlinear Michaelis-Menten empirical model for pre-dose concentrations, *MM-C₂* nonlinear
20 Michaelis-Menten empirical model for 2-h post-dose concentrations.

Electronic Supplementary Material

Supplementary Text S1 Target concentrations of CsA therapeutic monitoring

Target C_0 values were 200 - 350 ng mL⁻¹ in the first month, 150 - 300 ng mL⁻¹ during months 1 to 3, 100 - 250 ng mL⁻¹ during months 3 to 12, and 50 - 100 ng mL⁻¹ thereafter; target C_2 values were 1000 - 1500 ng mL⁻¹ in the first month, 800 - 1200 ng mL⁻¹ during months 1 to 3, 600 - 1000 ng mL⁻¹ during months 3 to 12, and 400 - 600 ng mL⁻¹ thereafter.

Supplementary Text S2 The semi-mechanistic model used to predict fat-free mass (FFM)

The semi-mechanistic model be used to predict FFM as follows [1]:

$$\text{FFM (male)} = \frac{9270 \times \text{WT}}{6680 + 216 \times \text{BMI}} \quad (1)$$

$$\text{FFM (female)} = \frac{9270 \times \text{WT}}{8780 + 244 \times \text{BMI}} \quad (2)$$

Where WT is measured in kilograms, BMI is calculated following the formula: BMI = weight (kg)/height² (m²), *BMI* body mass index, *WT* body weight

Supplementary Text S3 The derivation process of formula used to predict CsA plasma concentrations (C_u)

Assuming that C_u is the same both inside and outside the erythrocyte, then the concentration of drug in packed erythrocytes (C_e) is the combine of C_u and the concentration of drug bound to material in packed erythrocytes (C_{be}).

$$C_e = C_u + C_{be} \quad (3)$$

It is assumed that an equilibrium exists between C_u and drug bound to a single-site binding material associated with the erythrocyte,

$$C_{be} = \frac{nP_t \times C_u}{K_d + C_u} \quad (4)$$

Where P_t is the total concentration of binding material in packed erythrocytes, K_d is the equilibrium dissociation constant, and n is the number of binding sites per unit of binding material.

Combining Eqs. (3) and (4) gives

$$C_e = C_u + \frac{nP_t \times C_u}{K_d + C_u} \quad (5)$$

If C_{wb} is the total-blood concentration of drug, then by mass balance and considering a unit volume,

$$C_{wb} = C_p \times (1-HCT) + C_e \times HCT \quad (6)$$

If the function unbound (f_u) is independent of C_p , so that $C_u = f_u \times C_p$. With the parameter values estimated with real-world data before ($f_u = 0.0727$, $nP_t = 2562 \mu\text{g/L}$, $K_d = 67 \mu\text{g/L}$) [2], C_{wb} was related to C_p and haematocrit.

$$C_{wb} = (1 + 1.853 \times HCT) \times C_p \quad (7)$$

References

1. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. *Clinical pharmacokinetics* 2005; 44: 1051-65.
2. Legg B, Rowland M. Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment. *Pharmaceutical research* 1988; 5: 80-5.

Supplementary Table S1 A summary of parameters estimated by four final models using 2,000 bootstrap runs

Parameters	<i>Strategy I:</i> Linear compartmental model without incorporating DD		<i>Strategy II:</i> Linear compartmental model incorporating DD		<i>Strategy III:</i> Theory-based nonlinear compartmental model ^a		<i>Strategy IV:</i> Nonlinear MM empirical model			
	Mean	2.5 th -97.5 th percentiles	Mean	2.5 th -97.5 th percentiles	Mean	2.5 th -97.5 th percentiles	C ₀ Mean	2.5 th -97.5 th percentiles	C ₂ Mean	2.5 th -97.5 th percentiles
K _a (h ⁻¹)	1.25 (fixed)	/	1.25 (fixed)	/	1.25 (fixed)	/	/	/	/	/
CL/F (L h ⁻¹)	25.2	24.4-26.4	24.6	23.8-25.6	14.5	11.4	/	/	/	/
V·(FFM/50)/F (L)	162.0	149.2-167.5	162.0	150.1-167.9	254	17.2	/	/	/	/
K _m (ng ml ⁻¹)	/	/	/	/	/	/	45.8	20.1-70.4	183.8	107.6-257.1
V _m (mg day ⁻¹)	/	/	/	/	/	/	334.1	322.3-345.3	328.8	318.2-338.9
Covariate effect on CL/K _m ^c										
HCT	-0.406	-0.513--0.306	-0.355	-0.477--0.266	/	/	/	/	/	/
POD	0.00343	-0.0003-0.006	0.0122	0.006-0.014	0.0119	0.008-0.016	0.347	0.079-0.592	0.315	0.166-0.452
DD	/	/	0.282	0.116-0.335	3.4 ^b	2.8-4.0	/	/	/	/
	/	/	/	/	74.6 ^b	33.0-112.7	/	/	/	/
PD	/	/	/	/	1.08	1.05-1.10	/	/	/	/
ω _{CL/F} (%) / ω _{K_m} (%) ^c	22.9	15.1-25.7	20.0	14.0-23.6	19.0	13.9-23.2	107.8	75.5-131.3	103.6	78.0-123.9
η - shrinkage (%)	/	/	/	/	/	/	/	/	/	/
σ (%/ng ml ⁻¹) ^d	34.6	30.9-35.9	34.1	30.8-35.3	33.7	31.6-35.7	32.9	29.1-36.4	35.2	31.9-38.3
ε - shrinkage (%)	/	/	/	/	/	/	/	/	/	/

C₀, pre-dose concentration; C₂, 2-h post-dose concentration; CL/F, apparent clearance; DD, CsA daily dose; F, the bioavailability relative to 1; FFM, fat-free mass; HCT, haematocrit; K_a, absorption rate constant; K_m, steady-state concentrations at half-maximal dose rate; MM, Michaelis-Menten; PD, prednisolone daily dose; POD, postoperative days; V/F, apparent volume of distribution; V_m, maximum daily dose rate; ω, between subject variability; σ, residual variability.

^a The parameters estimated are expressed as plasma pharmacokinetic parameters in *Strategy III*


^b 3.4 is the maximum change in CL with increasing CsA daily dose; 74.6mg is the CsA daily dose with half maximum on CL

^c The parameters estimated in *Strategy I* and *II* are the results on apparent whole blood clearance; the parameters estimated in *Strategy III* are the results on apparent plasma clearance; the parameters estimated in *Strategy IV* are the results on K_m


^d Exponential error model is selected for *Strategies I-III* and additive error model is selected for *Strategy IV*

Electronic Supplementary Material


Supplementary Fig. S1




Supplementary Fig. S2a




Supplementary Fig. S2b




Supplementary Fig. S2c




Supplementary Fig. S2d




Supplementary Fig. S2e



Supplementary Fig. S2f



Supplementary Fig. S2g



Supplementary Fig. S2h

